DuPont has invested $10 million in its probiotics pilot facility in Wisconsin, which it said would help it ‘strengthen and embolden’ its position as a leading player in the probiotics industry.
The expansion at the site in Madison will allow DuPont to increase the pace of new product development, and significantly improves delivery times on pilot material for clinical trials and customer evaluations.
This in turn, the company said, improves overall scale-up capability and creates a more seamless transition to commercial-scale production.
DuPont Nutrition & Health president Matthias Heinzel said: “Given the explosive rise in demand for probiotics products all around the globe, this project allows us to aggressively pursue our goal to be the number one probiotics supplier in the world.
“These expansion efforts show our commitment to becoming bigger and stronger with our capability to meet demand, and our facilities, and qualified staff to handle the significant growth we foresee in this sector.”
The pilot area features new state-of-the-art equipment, data collection facilities, laboratories, instrumentation and specialised work space for probiotic development and scale up. The upgrades, which quadrupled the pilot area, have already increased bandwidth to simultaneously run more development projects while improving scale-up efficiency and time-to-market, DuPont said.
“With all the enhancements, we are better able to meet customer demand for new probiotics at a much faster pace,” said Kurt Fenster, bioprocess development group manager, culture manufacturing technology for DuPont. “Moving forward, we expect to substantially increase our speed to deliver products to customers.”
© FoodBev Media Ltd 2024